JP2010528050A5 - - Google Patents

Download PDF

Info

Publication number
JP2010528050A5
JP2010528050A5 JP2010509563A JP2010509563A JP2010528050A5 JP 2010528050 A5 JP2010528050 A5 JP 2010528050A5 JP 2010509563 A JP2010509563 A JP 2010509563A JP 2010509563 A JP2010509563 A JP 2010509563A JP 2010528050 A5 JP2010528050 A5 JP 2010528050A5
Authority
JP
Japan
Prior art keywords
formula
ring
compound
optionally substituted
hydrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2010509563A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010528050A (ja
JP5686596B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2008/064646 external-priority patent/WO2008147952A1/en
Publication of JP2010528050A publication Critical patent/JP2010528050A/ja
Publication of JP2010528050A5 publication Critical patent/JP2010528050A5/ja
Application granted granted Critical
Publication of JP5686596B2 publication Critical patent/JP5686596B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2010509563A 2007-05-25 2008-05-23 嚢胞性線維症膜貫通コンダクタンス制御因子の調節因子 Expired - Fee Related JP5686596B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US93177507P 2007-05-25 2007-05-25
US60/931,775 2007-05-25
US96870407P 2007-08-29 2007-08-29
US60/968,704 2007-08-29
PCT/US2008/064646 WO2008147952A1 (en) 2007-05-25 2008-05-23 Modulators of cystic fibrosis transmembrane conductance regulator

Publications (3)

Publication Number Publication Date
JP2010528050A JP2010528050A (ja) 2010-08-19
JP2010528050A5 true JP2010528050A5 (OSRAM) 2012-07-05
JP5686596B2 JP5686596B2 (ja) 2015-03-18

Family

ID=39798146

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010509563A Expired - Fee Related JP5686596B2 (ja) 2007-05-25 2008-05-23 嚢胞性線維症膜貫通コンダクタンス制御因子の調節因子

Country Status (10)

Country Link
US (3) US8399479B2 (OSRAM)
EP (1) EP2170901B1 (OSRAM)
JP (1) JP5686596B2 (OSRAM)
CN (1) CN101687883B (OSRAM)
AU (1) AU2008256717B2 (OSRAM)
CA (1) CA2688004C (OSRAM)
ES (1) ES2548292T3 (OSRAM)
HU (1) HUE025553T2 (OSRAM)
NZ (1) NZ581419A (OSRAM)
WO (1) WO2008147952A1 (OSRAM)

Families Citing this family (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA200602755B (en) 2003-09-06 2007-06-27 Vertex Pharma Modulators of ATP-binding cassette transporters
JP4869072B2 (ja) * 2003-11-14 2012-02-01 バーテックス ファーマシューティカルズ インコーポレイテッド Ａｔｐ結合カセットトランスポーターのモジュレーターとして有用なチアゾールおよびオキサゾール
US7977322B2 (en) 2004-08-20 2011-07-12 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
NZ587549A (en) * 2004-06-24 2012-10-26 Vertex Pharma 6-Amino-indole derivatives and processes for their preparation
EP1912983B1 (en) 2005-08-11 2011-06-08 Vertex Pharmaceuticals, Inc. Modulators of cystic fibrosis transmembrane conductance regulator
KR101331768B1 (ko) * 2005-11-08 2013-11-22 버텍스 파마슈티칼스 인코포레이티드 Ａｔｐ 결합 카세트 수송체의 헤테로사이클릭 조정제
CA2856037C (en) * 2005-12-28 2017-03-07 Vertex Pharmaceuticals Incorporated Modulators of atp-binding cassette transporters
US7671221B2 (en) * 2005-12-28 2010-03-02 Vertex Pharmaceuticals Incorporated Modulators of ATP-Binding Cassette transporters
CA2635581C (en) 2005-12-28 2017-02-28 Vertex Pharmaceuticals Incorporated Solid forms of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
US10022352B2 (en) 2006-04-07 2018-07-17 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
PL2674428T3 (pl) 2006-04-07 2017-01-31 Vertex Pharmaceuticals Incorporated Modulatory transporterów z kasetą wiążącą ATP
US7645789B2 (en) * 2006-04-07 2010-01-12 Vertex Pharmaceuticals Incorporated Indole derivatives as CFTR modulators
USRE50453E1 (en) 2006-04-07 2025-06-10 Vertex Pharmaceuticals Incorporated Indole derivatives as CFTR modulators
US8563573B2 (en) 2007-11-02 2013-10-22 Vertex Pharmaceuticals Incorporated Azaindole derivatives as CFTR modulators
CA2686838C (en) 2007-05-09 2017-03-14 Vertex Pharmaceuticals Incorporated Modulators of cftr
AU2008302598B2 (en) 2007-08-24 2014-07-17 Vertex Pharmaceuticals Incorporated Isothiazolopyridinones useful for the treatment of (inter alia) Cystic Fibrosis
JP5461405B2 (ja) * 2007-09-14 2014-04-02 バーテックス ファーマシューティカルズ インコーポレイテッド 嚢胞性線維症膜コンダクタンス制御因子の調節因子
SI2578571T1 (sl) 2007-11-16 2016-01-29 Vertex Pharmaceuticals Incorporated Izokinolinski modulatorji prenašalcev z atp-vezavno kaseto
DK2639223T3 (en) 2007-12-07 2017-06-19 Vertex Pharma Process for Preparation of Cycloalkylcarboxiamido-pyridine Benzoic Acids
HRP20170241T2 (hr) 2007-12-07 2023-03-17 Vertex Pharmaceuticals Incorporated Čvrsti oblici 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioksol-5-il)ciklopropankarboksamido)-3-metilpiridin-2-il)benzojeve kiseline
AU2008335439A1 (en) * 2007-12-07 2009-06-18 Vertex Pharmaceuticals Incorporated Formulations of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid
US20100036130A1 (en) 2007-12-07 2010-02-11 Vertex Pharmaceuticals Incorporated Processes for producing cycloalkylcarboxamido-pyridine benzoic acids
JP5637859B2 (ja) * 2007-12-13 2014-12-10 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ 嚢胞性線維症膜コンダクタンスレギュレーターのモジュレーター
NZ736561A (en) 2008-02-28 2018-02-23 Vertex Pharma Heteroaryl derivatives as cftr modulators
DK2615085T3 (en) 2008-03-31 2015-10-05 Vertex Pharma Pyridyl derivatives as CFTR modulators
US12458635B2 (en) 2008-08-13 2025-11-04 Vertex Pharmaceuticals Incorporated Pharmaceutical composition and administrations thereof
US20100074949A1 (en) 2008-08-13 2010-03-25 William Rowe Pharmaceutical composition and administration thereof
US8716338B2 (en) * 2008-09-29 2014-05-06 Vertex Pharmaceuticals Incorporated Dosage units of 3-(6-(1-(2,2-difluorobenzo[D] [1,3] dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid
UA104601C2 (uk) * 2008-10-23 2014-02-25 Вертекс Фармасьютікалз, Інкорпорейтед Модулятори регулятора трансмембранної провідності при муковісцидозі
EP2382197B1 (en) 2008-12-30 2016-10-05 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
PL2408750T3 (pl) 2009-03-20 2016-02-29 Vertex Pharma Sposób otrzymywania modulatorów błonowego regulatora przewodnictwa swoistego dla mukowiscydozy
US8802868B2 (en) 2010-03-25 2014-08-12 Vertex Pharmaceuticals Incorporated Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide
DK3150198T3 (da) 2010-04-07 2021-11-01 Vertex Pharma Farmaceutiske sammensætninger af 3-(6-(1-(2,2-difluorbenzo[d][1,3]dioxol-5-yl)-cyclopropancarboxamido)-3-methylpyriodin-2-yl)benzoesyre og indgivelse deraf
RS54783B1 (sr) 2010-04-07 2016-10-31 Vertex Pharma Čvrste forme 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioksol-5-il)ciklopropankarboksiamido)-3-metilpiridin-2-il)benzoeve kiseline
CA2797118C (en) 2010-04-22 2021-03-30 Vertex Pharmaceuticals Incorporated Process of producing cycloalkylcarboxamido-indole compounds
US8563593B2 (en) 2010-06-08 2013-10-22 Vertex Pharmaceuticals Incorporated Formulations of (R)-1-(2,2-difluorobenzo[D] [1,3] dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide
MX357328B (es) 2011-11-08 2018-07-05 Vertex Pharma Moduladores de trasportadores de casete enlazante de atp.
AU2013226076B2 (en) 2012-02-27 2017-11-16 Vertex Pharmaceuticals Incorporated Pharmaceutical composition and administration thereof
US8674108B2 (en) 2012-04-20 2014-03-18 Vertex Pharmaceuticals Incorporated Solid forms of N-[2,4-bis(1,1-dimethylethy)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
EP2872122A1 (en) 2012-07-16 2015-05-20 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions of (r)-1-(2,2-diflurorbenzo[d][1,3]dioxol-5-yl)-n-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1h-indol-5-yl) cyclopropanecarboxamide and administration thereof
MX2015015421A (es) 2013-05-10 2016-06-21 Nimbus Apollo Inc Inhibidores de acetil-coa carboxilasa (acc) y usos de los mismos.
WO2014182945A1 (en) 2013-05-10 2014-11-13 Nimbus Apollo, Inc. Acc inhibitors and uses thereof
US10208044B2 (en) 2013-05-10 2019-02-19 Gilead Apollo, Llc ACC inhibitors and uses thereof
AU2014262636A1 (en) * 2013-05-10 2015-11-26 Gilead Apollo, Llc ACC inhibitors and uses thereof
RU2718044C2 (ru) 2013-11-12 2020-03-30 Вертекс Фармасьютикалз Инкорпорейтед Способ получения фармацевтических композиций для лечения опосредованных cftr заболеваний
RS62140B1 (sr) 2014-04-15 2021-08-31 Vertex Pharma Farmaceutske kompozicije za lečenje bolesti posredovanih transmembranskim regulatorom provodljivosti cistične fibroze
KR101905295B1 (ko) * 2014-06-03 2018-10-05 노파르티스 아게 나프티리딘디온 유도체
KR20170063954A (ko) 2014-10-07 2017-06-08 버텍스 파마슈티칼스 인코포레이티드 낭성 섬유증 막횡단 전도도 조절자의 조정제의 공-결정
MX2017005663A (es) 2014-10-31 2018-03-01 Abbvie Sarl Tetrahidropiranos sustituidos y metodo de uso.
HRP20211194T1 (hr) 2014-11-18 2021-10-29 Vertex Pharmaceuticals Inc. Postupak za provođenje testova velike propusnosti putem tekućinske kromatografije visoke djelotvornosti
BR112017026132A2 (pt) 2015-06-02 2018-08-28 AbbVie S.à.r.l. piridinas substituídas e métodos de uso
US9840513B2 (en) 2015-07-16 2017-12-12 Abbvie S.Á.R.L. Substituted tricyclics and method of use
WO2017060874A1 (en) 2015-10-09 2017-04-13 Abbvie S.Á.R.L N-sulfonylated pyrazolo[3,4-b]pyridin-6-carboxamides and method of use
US10130622B2 (en) 2015-10-09 2018-11-20 Abbvie S.Á.R.L. Compounds for treatment of cystic fibrosis
EP3359539A1 (en) 2015-10-09 2018-08-15 AbbVie S.À.R.L. Substituted pyrazolo[3,4-b]pyridin-6-carboxylic acids and their use
EP3448842A1 (en) 2016-04-26 2019-03-06 AbbVie S.À.R.L. Modulators of cystic fibrosis transmembrane conductance regulator protein
US10138227B2 (en) 2016-06-03 2018-11-27 Abbvie S.Á.R.L. Heteroaryl substituted pyridines and methods of use
US9981910B2 (en) 2016-10-07 2018-05-29 Abbvie S.Á.R.L. Substituted pyrrolidines and methods of use
US10399940B2 (en) 2016-10-07 2019-09-03 Abbvie S.Á.R.L. Substituted pyrrolidines and methods of use
WO2018116185A1 (en) 2016-12-20 2018-06-28 AbbVie S.à.r.l. Deuterated cftr modulators and methods of use
TW201831471A (zh) 2017-02-24 2018-09-01 盧森堡商艾伯維公司 囊腫纖化症跨膜傳導調節蛋白的調節劑及其使用方法
US10988454B2 (en) 2017-09-14 2021-04-27 Abbvie Overseas S.À.R.L. Modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use
WO2019193062A1 (en) 2018-04-03 2019-10-10 Abbvie S.Á.R.L Substituted pyrrolidines and their use
US11345691B2 (en) 2019-06-03 2022-05-31 AbbVie Global Enterprises Ltd. Prodrug modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use
US11236067B2 (en) 2019-07-12 2022-02-01 Orphomed, Inc. Compound for treating cystic fibrosis
CN114423769B (zh) 2019-09-20 2024-04-26 Sabic环球技术有限责任公司 用于生产聚烯烃的催化剂组合物中的化合物
IL292965A (en) 2019-11-12 2022-07-01 Genzyme Corp 6-membered heteroarylaminosulfonamides and methods of use
WO2021113809A1 (en) 2019-12-05 2021-06-10 Genzyme Corporation Arylamides and methods of use thereof
WO2021113806A1 (en) 2019-12-05 2021-06-10 Genzyme Corporation Arylamides and methods of use thereof
CR20230120A (es) 2020-08-07 2023-09-01 Vertex Pharma Moduladores del regulador de la conductancia transmembrana de la fibrosis quística
US12324802B2 (en) 2020-11-18 2025-06-10 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
US20220213041A1 (en) 2021-01-06 2022-07-07 AbbVie Global Enterprises Ltd. Modulators of the Cystic Fibrosis Transmembrane Conductance Regulator Protein and Methods of Use
EP4274828A1 (en) 2021-01-06 2023-11-15 AbbVie Global Enterprises Ltd. Modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use
EP4396179A1 (en) 2021-09-03 2024-07-10 Genzyme Corporation Indole compounds and methods of use
EP4396176A1 (en) 2021-09-03 2024-07-10 Genzyme Corporation Indole compounds and uses thereof in the treatement of cystic fibrosis
WO2024054845A1 (en) 2022-09-07 2024-03-14 Sionna Therapeutics Macrocycic compounds, compositions, and methods of using thereof
AU2023338225A1 (en) 2022-09-07 2025-03-20 Genzyme Corporation Macrocyclic compounds, compositions, and methods of using thereof
WO2024054851A1 (en) 2022-09-07 2024-03-14 Sionna Therapeutics Macrocyclic compounds, compositions and methods of using thereof
WO2025132358A1 (en) 2023-12-21 2025-06-26 Galapagos Nv Novel compounds and pharmaceutical compositions thereof for the treatment of infectious diseases

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5284661A (en) * 1990-02-22 1994-02-08 Takeda Chemical Industries, Ltd. Fused thiophene derivatives, their production and use
JP2699794B2 (ja) * 1992-03-12 1998-01-19 三菱化学株式会社 チエノ〔３，２−ｂ〕ピリジン誘導体
EP1235565B1 (en) * 1999-11-23 2005-12-28 Janssen Pharmaceutica N.V. Use of 5ht 3 agonists for relaxing the fundus
AU2005251745A1 (en) * 2004-06-04 2005-12-22 The Regents Of The University Of California Compounds having activity in increasing ion transport by mutant-CFTR and uses thereof
NZ587549A (en) * 2004-06-24 2012-10-26 Vertex Pharma 6-Amino-indole derivatives and processes for their preparation

Similar Documents

Publication Publication Date Title
JP2010528050A5 (OSRAM)
JP2011506474A5 (OSRAM)
JP2007519740A5 (OSRAM)
JP2012514038A5 (OSRAM)
JP2010539185A5 (OSRAM)
JP2008504291A5 (OSRAM)
JP2013245219A5 (OSRAM)
JP2010526831A5 (OSRAM)
US11655226B2 (en) KDM1A inhibitors for the treatment of disease
JP2009521468A5 (OSRAM)
JP2011516420A5 (OSRAM)
JP2009522277A5 (OSRAM)
RU2010114732A (ru) Твердые формы n-[2,4-бис(1,1-диметилэтил)-5-гидроксифенил]-1,4-дигидро-4-оксохинолин-3-карбоксамида
JP2012521362A5 (OSRAM)
CN106536529B (zh) 硼酸衍生物及其治疗用途
JP5686596B2 (ja) 嚢胞性線維症膜貫通コンダクタンス制御因子の調節因子
RU2011122646A (ru) Модуляторы переносчиков атф-связывающих кассет
SI3091011T1 (en) Modulators of ATP conveyor belt conveyors
WO2010117089A3 (en) Antimycotic pharmaceutical composition
ME02799B (me) Modulatori ATP-vezujućih kasetnih transportera
JP2011505338A5 (OSRAM)
ES2889916T3 (es) Un procedimiento para la preparación de pirroles con actividades hipolipidémicas e hipocolesterémicas
JP2007509044A5 (OSRAM)
RU2008122929A (ru) Гетероциклические модуляторы транспортеров атф-связывающей кассеты
RU2006120549A (ru) Тиазолы и оксазолы, применяемые в качестве модуляторов транспортеров арт-связывающей кассеты